CSL Biotherapies Begins Shipment of Seasonal Influenza Vaccine for 2009-2010 Season

Strategic Insights -

CSL Biotherapies, a leading manufacturer of thimerosal-free seasonal influenza vaccine, has initiated shipment of its seasonal influenza virus vaccine to U.S. distributors for the 2009-2010 season. The company plans to deliver over eight million doses of the vaccine, primarily in single-dose, thimerosal-free, pre-filled syringes. This early delivery demonstrates CSL Biotherapies' ability to rapidly optimize vaccine production to meet evolving public health needs. The company is also working with the U.S. government to develop a vaccine to address the H1N1 pandemic, and has initiated human clinical trials of the H1N1 influenza vaccine.

Key Takeaways:

  • CSL Biotherapies has begun shipment of its seasonal influenza virus vaccine to U.S. distributors for the 2009-2010 season, with plans to deliver over eight million doses.
  • The majority of the vaccine will be in single-dose, thimerosal-free, pre-filled syringes.
  • The company's early delivery demonstrates its ability to rapidly optimize vaccine production in response to evolving public health needs.
  • CSL Biotherapies is working with the U.S. government to develop a vaccine to address the H1N1 pandemic.
  • The company has initiated human clinical trials of the H1N1 influenza vaccine.
  • Paul Perreault, President of CSL Biotherapies, emphasized the company's expertise in influenza vaccine development and manufacturing, which has been accumulated over 40 years.
  • CSL Limited, the parent company of CSL Biotherapies, is the first vaccine manufacturer to initiate human clinical trials of the H1N1 influenza vaccine.

Statistics:

  • Over eight million doses of seasonal influenza virus vaccine will be delivered to U.S. distributors for the 2009-2010 season.
  • The majority of the vaccine will be in single-dose, thimerosal-free, pre-filled syringes.
  • CSL Biotherapies has 10,000 employees operating in 27 countries worldwide.
  • The company has 40 years of experience in influenza vaccine development and manufacturing.
  • CSL Limited has initiated human clinical trials of the H1N1 influenza vaccine in July 2009 in Australia, with U.S. clinical studies expected to commence in mid-August.

Sources:

  • CSL Biotherapies
  • CSL Limited
  • NewsRx.com
  • Vaccine Weekly